Arteriosclerosis obliterans associated with anti-cardiolipin antibody/ β2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus

Rheumatology

Volumn 47, Issue 5, 2008, Pages 684-689

  Nojima, J ^a   Masuda, Y ^a   Iwatani, Y ^b   Kuratsune, H ^c   Watanabe, Y ^d   Suehisa, E ^a   Takano, T ^a   Hidaka, Y ^a   Kanakura, Y ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANSAI UNIVERSITY OF WELFARE SCIENCES   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti phospholipid antibodies; Arteriosclerosis obliterans; Cerebral vascular disorder; Ischaemic heart disease; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ARTERIOSCLEROSIS OBLITERANS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHOSPHATIDYLSERINES; PREVALENCE; PROTHROMBIN; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 42949158193     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken124     Document Type: Article

References (39)

1. Nojima J, Kuratsune H, Suehisa E et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus, erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47:1008-15.
2. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A now view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood 1994;84:2854-67.
3. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
4. Matsuura E, Igarashi Y, Fujimoto M et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885-91.
5. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2- glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
7. Atsumi T, leko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
8. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of antiphosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006;91:699-702.
9. Galli M, Barbui T. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:2149-57.
10. Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: Predictive value of laboratory tests. Thromb Haemost 1997;78:75-8.
11. Triplett DA. Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters. Lupus 1996;5:431-5.
12. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003;101:1827-32.
13. Ginsberg JS, Wells PS, Bill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
14. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-53.
15. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
16. Koike T, Bohgaki M, Amengual O, Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28:129-33.
17. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005;257:485-95.
18. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-15.
19. Roman MJ, Shenker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
20. Ahmad Y, Shelmerdine J, Bodill H et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8.
21. Ardoin S, Sandborg C, Schanberg L. Review. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007;16:618-26.
22. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
23. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
24. Sherer Y, Shoenfeld Y. Mechanisms of disease: Atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106.
25. Wolberg AS, Roubey RA. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004;114:391-6.
26. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:620-32.
27. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:617-23.
28. Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: Plaque to attack. Trends Immunol 2005;26:550-6.
29. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107:569-73.
30. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998,79:276-81.
31. Dobado-Berrios PM, Lopez-Pedrera C, Velasco, F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999;82:1578-82.
32. Ferro D, Saliola M, Meroni PL et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: Effect of antioxidant treatment. J Thromb Haemost 2003;1:523-31.
33. Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993;83:466-72.
34. Lopez-Pedrera C, Buendia P, Cuadrado MJ et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-11.
35. Roubey RA. Tissue factor pathway and the antiphospholipid syndrome. J Autoimmun 2000;15:217-20.
36. Yasuda S, Bohgaki M, Atsumi T, Koike T. Pathogenesis of antiphospholipid antibodies: Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 2005;210:775-80.
37. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001;115:451-9.
38. Wang L, Su CY, Chou KY, Wang CT. Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies. Br J Haematol 2002;118:1152-62.
39. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies - Co-existence of these antibodies enhances ADP-induced platelet activation in vitro, Thromb Haemost 2004;91:967-76.